Sobrera Pharma and Recipharm have come together into an agreement.
FREMONT, CA: Sobrera Pharma, a Swedish life science company, and global contract development and manufacturing organization (CDMO), Recipharm, have joined hands into an agreement for the formulation, development, and manufacturing of SO-001, an oral treatment for Alcohol Use Disorder (AUD).
Phase II of the study is already ongoing to how the new therapy’s efficacy and safety, which acts via dopamine, play an important part in the reward system. Preclinical and the clinical data form the basis for developing a one-of-a-kind new product to be developed at Recipharm’s Centre of Excellence in Oral Solids that offers access to the first-class expertise experience in the development and manufacturing of drug product.
Bernard Pluta, President, Development Services at Recipharm, says, “Alcohol addiction is a common but serious health problem all over the world, lacking effective treatments. As such there is strong demand for new and improved therapies to help better manage this condition. We are very proud to be able to work with Sobrera on such an important project and we believe that our excellent capabilities at our Centre of Excellence in Oral Solids, will be very valuable assets throughout the partnership”.
Commenting on the partnership, Ann-Charlotte Rosendahl, CEO of Sobrera, states, “Increased alcohol intake is strongly related to increased mortality and morbidity and, every year over 3 million people globally die in alcohol related illnesses and accidents. A more efficacious, easy to use product, is much needed to reduce high risk alcohol consumption. This product potentially offers us an opportunity to bring significant value to patients and family and to lessen the socio-economic burden of AUD.”
“The decision to commence the collaboration and start formulation development, marks an important milestone for our company and we’re delighted to be working with Recipharm on this important development work”.